Nanotechnology applications to HIV vaccines and microbicides

Journal of Global Infectious Diseases

Volumn 4, Issue 1, 2012, Pages 62-68

  Boyapalle, Sandhya ^a   Mohapatra, Subhra ^a   Mohapatra, Shyam ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

HIV; Microbicides; Nanotechnology; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; ALVAC; CHITOSAN; DNA VACCINE; DRUG CARRIER; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOMODULATING AGENT; LIPOSOME; MICROBICIDE; NEF PROTEIN; PLACEBO; POL PROTEIN; POLYGLACTIN; RECOMBINANT GLYCOPROTEIN GP 120; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHINITIS; VACCINE FAILURE; VIRUS INFECTION;

EID: 84858844271     PISSN: 0974777X     EISSN: 09748245     Source Type: Journal    
DOI: 10.4103/0974-777X.93764     Document Type: Article

References (50)

1. -2007 AIDS epidemic update. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS).
2. Baba TW, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-6.
3. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008;105:7552-7.
4. Keele BF, Tazi L, Gartner S, Liu Y, Burgon TB, Estes JD, et al. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J Virol 2008;82:5548-61.
5. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009;83:3556-67.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
7. McDougal JS, Mawle A, Cort SP, Nicholson JK, Cross GD, Scheppler-Campbell JA, et al. Cellular tropism of the human retrovirus HTLV-III/ LAV. I. Role of T cell activation and expression of the T4 antigen. J Immunol1985;135:3151-62.
8. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006;18:399-405.
9. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-71.
10. Billich A. AIDSVAX VaxGen. Curr Opin Investig Drugs 2004;5:214-21.
11. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006;6:930-9.
12. Robinson HL. HIV/AIDS vaccines: 2007. Clin Pharmacol Ther 2007;82:686-93.
13. Phogat S, Wyatt RT, Karlsson Hedestam GB. Inhibition of HIV-1 entry by antibodies: Potential viral and cellular targets. J Intern Med 2007;262:26-43.
14. McMichael AJ. HIV vaccines. Annu Rev Immunol 2006;24:227-55.
15. Emini EA, Koff WC. AIDS/HIV. Developing an AIDS vaccine: Need, uncertainty, hope. Science 2004;304:1913-4.
16. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, Xu L, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIVchallenged monkeys. Science 2006;312:1530-3.
17. Thorner AR, Barouch DH. HIV-1 vaccine development: Progress and prospects. Curr Infect Dis Rep 2007;9:71-5.
18. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-60.
19. Bernard NF, Pederson K, Chung F, Ouellet L, Wainberg MA, Tsoukas CM. HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons. AIDS 1998;12:2125-39.
20. Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, et al. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: A predominant gag-specific response is associated with nonprogressive infection. J Infect Dis 1998;178:1008-18.
21. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature 2002;415:331-5.
22. Sekaly RP. The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development? J Exp Med 2008;205:7-12.
23. Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008;205:63-77.
24. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93.
25. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: A case-cohort analysis. Lancet 2008;372:1894-905.
26. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-20.
27. Kumar M, Behera AK, Lockey RF, Zhang J, Bhullar G, De La Cruz CP, et al. Intranasal gene transfer by Chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther 2002;13:1415-25.
28. Zhang W, Yang H, Kong X, Mohapatra S, San Juan-Vergara H, Hellermann G, et al. Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med 2005;11:56-62.
29. Kumar A, Jena PK, Behera S, Lockey RF, Mohapatra S, Mohapatra S. Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine 2010;6:64-9.
30. Moingeon P, de Taisne C, Almond J. Delivery technologies for human vaccines. Br Med Bull 2002;62:29-44.
31. Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 2002;14:666-72.
32. Borchard G. Chitosans for gene delivery. Adv Drug Deliv Rev 2001;52:145-50.
33. Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. Chitosan-based vector/DNA complexes for gene delivery: Biophysical characteristics and transfection ability. Pharm Res 1998;15:1332-9.
34. Sugitachi A, Kashiwaba M, Shimada Y, Terashima M, Asahi H, Saitoh K, et al. Novel biodegradable materials for drug delivery systems (DDS). Gan To Kagaku Ryoho 2001;28:1530-3.
35. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 2006;1:117-28.
36. Antonov SF, Filippov YI, Shinkarev SM, Frolova MA. Study of woundhealing properties of chitosan. Russian Agric Sci 2008;34:426-7.
37. Roller S, Covill N. The Antimicrobial properties of chitosan in mayonnaise and mayonnaise-based shrimp salads. J Food Prot 2000;63:202-9.
38. Leong KW, Mao HQ, Truong-Le VL, Roy K, Walsh SM, August JT. DNApolycation nanospheres as non-viral gene delivery vehicles. J Control Release 1998;53:183-93.
39. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001;51:81-96.
40. Borchard G, Junginger HE. Modern drug delivery applications of chitosan. Adv Drug Deliv Rev 2001;52:103.
41. Schipper NG, Olsson S, Hoogstraate JA, deBoer AG, Varum KM, Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: Mechanism of absorption enhancement. Pharm Res 1997;14:923-9.
42. Kim SK, Park PJ, Yang HP, Han SS. Subacute toxicity of chitosan oligosaccharide in Sprague-Dawley rats. Arzneimittelforschung 2001;51:769-74.
43. Anzai N, Taniyama T, Nakandakari N, Sugiyama C, Negishi T, Hayatsu H, et al. Inhibition of DNA adduct formation and mutagenic action of 3-amino-1-methyl-5h-pyrido[4,3-b]indole by chlorophyllin-chitosan in rpsL transgenic mice. Jpn J Cancer Res 2001;92:848-53.
44. Masuko T, Minami A, Iwasaki N, Majima T, Nishimura S, Lee YC. Thiolation of chitosan. Attachment of proteins via thioether formation. Biomacromolecules 2005;6:880-4.
45. Lee D, Zhang W, Shirley SA, Kong X, Hellermann GR, Lockey RF. Thiolated Chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery. Pharm Res 2006;24:157-67.
46. Ho YC, Wu SJ, Mi FL, Chiu YL, Yu SH, Panda N, et al. Thiol-Modified chitosan sulfate nanoparticles for protection and release of basic fibroblast growth factor. Bioconjug Chem 2010;21:28-38.
47. Le Buanec H, Vetu C, Lachgar A, Benoit MA, Gillard J, Paturance S, et al. Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes. Biomed Pharmacother 2001;55:316-20.
48. Locher CP, Witt SA, Ashlock BM, Levy JA. Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine. DNA Cell Biol 2004;23:107-10.
49. Drogoz A, Munier S, Verrier B, David L, Domard A, Delair T. Towards biocompatible vaccine delivery systems: Interactions of colloidal PECs based on polysaccharides with HIV-1 p24 antigen. Biomacromolecules 2008;9:583-91.
50. Weber C, Drogoz A, David L, Domard A, Charles MH, Verrier B, et al. Polysaccharide-based vaccine delivery systems: Macromolecular assembly, interactions with antigen presenting cells, and in vivo immunomonitoring. J Biomed Mater Res A 2010;93:1322-34.